Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Dec 06, 2022 10:40am
197 Views
Post# 35153280

RE:RE:RE:Thera management unseen after the disaster !

RE:RE:RE:Thera management unseen after the disaster !LouisW - Below is an excerpt from the response.  

"We too share your frustration with the current market conditions and the price Thera shares are trading at.   We are also very aware and saddened by the toll the market is having on our shareholders and we wish markets were better. It is small comfort that we are not alone, but in a sector that is going through the worst period it has ever seen.  That said,  I have attached for your reference a Bloomberg snapshot graph of how we are doing against the XBI index, and it does give us a quantum of hope.
 
As you know, Theratechnologies has grown and changed over the years, and we have an exceptional leader in Paul today.  He is well recognized and respected; his global experience is appreciated by investors and analysts alike.  Under his leadership we have made strides and taken strategic steps which we believe lays the foundation for strategic growth.  In terms of activity, what we can tell you is that our team has been working incredibly hard over the past year to drive shareholder value through many meetings with numerous quality investors and developing new analysts on both sides of the border.  We are getting traction and are very optimistic we will have new analysts covering us soon. 
 
The big takeaways from our meetings have been that:
 
  • Our quarterly and year to date growth in the commercial business has been delivering exceptional results,  and we will continue to do so for the foreseeable future. In fact, our commercial line of business is what investors and analysts are noticing about us as a differentiator.
 
  • Our TH1902 program is advancing and we are working with some of the best oncologists and medical centres in the world.  Additionally, our scientific advisors are world renowned leaders, one investor recently told me that of all the companies in the world it is impressive that Dr. Mace Rothenberg chose to work with us.
 
  • We have a phase three NASH program that we believe will be extremely successful with the right partner, who will bring resources and capabilities and join us on our journey of success.
 
  • Our largest shareholders have added to their positions over the past couple of years, and have been supportive of management.
 
  • We were able to execute a non-dilutive financing with Marathon, one of the largest healthcare investors, and that is a testament to Philippe’ expertise as an experienced CFO.
 
  • We are actively seeking new relationships with new tier one investors and analysts for research coverage.
 
In terms of communications, we are working with a very strong team at LifeSci Advisors and have engaged specialized boutique firms for our PR and comms needs."

LouisW wrote: Just curious...What does nice response mean? What did they reply? And may i request one copy of the report? HYWang1105@gmail.com  Thank you.

I almost lose my faith to THTX...exceedingly frustrating. I am curious about What Soleus ad Morgan Stanley are wondering....


PWIB123 wrote: This is the biggest issue I have for sure.  The markets may have given a chunk of the loss back if they would simply address it.  I had corresponded briefly with IR recently sharing my disappointment with the lack of openness and begging them to be sure to update prior to year-end.  I got a very nice response.  And then that Cantor report came out, and she emailed me a copy, which I felt like was reassurance they were on the right path and would indeed have something to announce soon.  Then this!  I have already shared with them that I cannot believe that PR wasn't accompanied by a conference call.  No response this time.  

JayjayUSA12007 wrote: It's strange to me that Thera managment did not even try to calm the market.
Normally, other public companies would have called a conference call to explain the issue(s) to show its fiduciary duty to shareholders.
This managment just "ghosted" it. Pooff !! disappeared like a little kid throwing a stone into a glass window by accident, but too scared to come forward.
I am deeply disappointed...

 




<< Previous
Bullboard Posts
Next >>